Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2004 Oct 23;329(7472):968-70.
doi: 10.1136/bmj.329.7472.968.

The PROGRESS trial three years later: time for a balanced report of effectiveness

Richard Wennberg  1 , Camilla Zimmermann
Affiliations

The PROGRESS trial three years later: time for a balanced report of effectiveness

Richard Wennberg et al. BMJ. .

Abstract

Has the use of the phrase “perindopril based blood pressure lowering regimen” resulted in an oversimplistic and hence inaccurate interpretation of the results of the PROGRESS trial creeping into the literature and clinical practice?

PubMed Disclaimer

Figures

Figure 1
Figure 1
In the PROGRESS trial, the phrases “active treatment” or “perindopril-based blood-pressure-lowering regimen” refer to amalgamated data from the perindopril alone and perindopril plus indapamide treatment arms. Perindopril alone provided no detectable benefits. Reproduced with permission from Elsevier
See this image and copyright information in PMC

Comment in

References

    1. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with a previous stroke or transient ischaemic attack. Lancet 2001;358: 1033-41. - PubMed
    1. Staessen JA, Wang J. Blood-pressure lowering for the secondary prevention of stroke [comment]. Lancet 2001;358: 1026-7. - PubMed
    1. Cates C. The lowering of blood pressure after stroke [letter]. Lancet 2001;358: 1993. - PubMed
    1. Tirschwell D. Combined therapy with indapamide and perindopril but not perindopril alone reduced the risk for recurrent stroke. ACP J Club 2002;136: 51. - PubMed
    1. Psaty BM, Weiss NS, Furberg CD. The PROGRESS trial: questions about the effectiveness of angiotensin converting enzyme inhibitors. Am J Hypertens 2002;15: 472-4. - PubMed

MeSH terms